PepGen says early data from a small study of its muscular dystrophy treatment look promising. Across the limited trial findings, the company reports that its therapy is showing signs of correcting disease-related genetic “stutter” associated with myotonic dystrophy type 1.
Both outlets highlight that the results are preliminary and come from early testing, not larger, confirmatory trials. BioPharma Dive adds a comparative angle by noting that the early results appear to compare favorably with other RNA-based medicines that have been tested at or associated with major industry players, including Novartis and Dyne Therapeutics. STAT News focuses more directly on the mechanism-specific claim, stating that PepGen’s candidate corrects more of the genetic stutter than expected in the early study.
Together, the coverage centers on early efficacy signals, the disease target (myotonic dystrophy type 1), and how the company’s reported level of genetic correction distinguishes its approach, while still underscoring the small, early nature of the data.
